LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Atvērts

SektorsVeselības aprūpe

3.75 -1.57

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.71

Max

3.82

Galvenie mērījumi
By Trading Economics
Ienākumi	-26M -34M
Pārdošana	-9.4M 200M
EPS	-0.09
Peļņas marža	-17.016
Darbinieki	2,700
EBITDA	43M -18M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+96.34% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-122M 345M
Iepriekšējā atvēršanas cena	5.32
Iepriekšējā slēgšanas cena	3.75

Ziņu noskaņojums

By Acuity

44%

56%

138 / 345 Rangs Healthcare

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. maijs 08:24 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026. g. 25. maijs 21:22 UTC

Peļņas

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026. g. 25. maijs 20:50 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:20 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:01 UTC

Tirgus saruna

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026. g. 25. maijs 14:43 UTC

Tirgus saruna

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026. g. 25. maijs 14:15 UTC

Tirgus saruna

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026. g. 25. maijs 13:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 25. maijs 12:58 UTC

Tirgus saruna

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026. g. 25. maijs 12:56 UTC

Tirgus saruna

Peļņas

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 25. maijs 12:34 UTC

Tirgus saruna

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026. g. 25. maijs 12:10 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero's Assets Look Strategic -- Market Talk

2026. g. 25. maijs 11:00 UTC

Tirgus saruna

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026. g. 25. maijs 10:19 UTC

Tirgus saruna

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026. g. 25. maijs 10:05 UTC

Peļņas

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026. g. 25. maijs 10:04 UTC

Peļņas

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026. g. 25. maijs 10:03 UTC

Peļņas

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026. g. 25. maijs 10:02 UTC

Peļņas

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026. g. 25. maijs 10:01 UTC

Peļņas

Tenaga Nasional 1Q Net Up 3.7% on Year

2026. g. 25. maijs 10:00 UTC

Peļņas

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q EPS MYR0.1883

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Rev MYR17.1B

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Net MYR1.1B

2026. g. 25. maijs 09:38 UTC

Tirgus saruna

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026. g. 25. maijs 08:55 UTC

Tirgus saruna

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

96.34% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 96.34%

Augstākais 10 USD

Zemākais 5.5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

138 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.